WallStreetZenWallStreetZen

NASDAQ: AXDX
Accelerate Diagnostics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for AXDX

Based on 1 analyst offering 12 month price targets for Accelerate Diagnostics Inc.
Min Forecast
$1.00-32.43%
Avg Forecast
$1.00-32.43%
Max Forecast
$1.00-32.43%

Should I buy or sell AXDX stock?

Based on 1 analyst offering ratings for Accelerate Diagnostics Inc.
Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AXDX stock forecasts and price targets.

AXDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01

1 of 1

Forecast return on equity

Is AXDX forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is AXDX forecast to generate an efficient return on assets?
Company
-177.08%
Industry
9.72%
AXDX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AXDX earnings per share forecast

What is AXDX's earnings per share in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$2.14
Avg 2 year Forecast
-$1.71

AXDX revenue forecast

What is AXDX's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$12.0M-1.9%
Avg 2 year Forecast
$12.5M+2.18%
AXDX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AXDX revenue growth forecast

How is AXDX forecast to perform vs Medical Devices companies and vs the US market?
Company
-1.9%
Industry
4.71%
Market
10%
AXDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AXDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AXDX vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
AXDX$1.48$1.00-32.43%Hold
MOVE$0.36$2.00+461.80%Buy
RPID$0.83N/AN/A
RBOT$6.19$10.00+61.55%Hold
APYX$1.08N/AN/A
View Top Medical Device Stocks

Accelerate Diagnostics Stock Forecast FAQ

Is Accelerate Diagnostics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: AXDX) stock is to Hold AXDX stock.

Out of 1 analyst, 0 (0%) are recommending AXDX as a Strong Buy, 0 (0%) are recommending AXDX as a Buy, 1 (100%) are recommending AXDX as a Hold, 0 (0%) are recommending AXDX as a Sell, and 0 (0%) are recommending AXDX as a Strong Sell.

If you're new to stock investing, here's how to buy Accelerate Diagnostics stock.

What is AXDX's earnings growth forecast for 2024-2025?

(NASDAQ: AXDX) Accelerate Diagnostics's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 74.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.18%.

Accelerate Diagnostics's earnings in 2024 is -$37,906,000.On average, 1 Wall Street analyst forecast AXDX's earnings for 2024 to be -$50,673,880, with the lowest AXDX earnings forecast at -$50,673,880, and the highest AXDX earnings forecast at -$50,673,880.

In 2025, AXDX is forecast to generate -$40,491,745 in earnings, with the lowest earnings forecast at -$40,491,745 and the highest earnings forecast at -$40,491,745.

What is AXDX's revenue growth forecast for 2024-2025?

(NASDAQ: AXDX) Accelerate Diagnostics's forecast annual revenue growth rate of -1.9% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 4.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10%.

Accelerate Diagnostics's revenue in 2024 is $12,233,000.On average, 1 Wall Street analysts forecast AXDX's revenue for 2024 to be $284,152,596, with the lowest AXDX revenue forecast at $284,152,596, and the highest AXDX revenue forecast at $284,152,596.

In 2025, AXDX is forecast to generate $295,992,288 in revenue, with the lowest revenue forecast at $295,992,288 and the highest revenue forecast at $295,992,288.

What is AXDX's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: AXDX) forecast ROA is -177.08%, which is lower than the forecast US Medical Devices industry average of 9.72%.

What is AXDX's Price Target?

According to 1 Wall Street analyst that have issued a 1 year AXDX price target, the average AXDX price target is $1.00, with the highest AXDX stock price forecast at $1.00 and the lowest AXDX stock price forecast at $1.00.

The Wall Street analyst predicted that Accelerate Diagnostics's share price could fall to $1.00 by Apr 1, 2025. The average Accelerate Diagnostics stock price prediction forecasts a potential downside of 32.43% from the current AXDX share price of $1.48.

What is AXDX's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: AXDX) Accelerate Diagnostics's current Earnings Per Share (EPS) is -$1.99. On average, analysts forecast that AXDX's EPS will be -$2.14 for 2024, with the lowest EPS forecast at -$2.14, and the highest EPS forecast at -$2.14. In 2025, AXDX's EPS is forecast to hit -$1.71 (min: -$1.71, max: -$1.71).

What is AXDX's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: AXDX) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.